Clinical Trials Logo

Neoplasms, Basal Cell clinical trials

View clinical trials related to Neoplasms, Basal Cell.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04928222 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

Start date: September 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic location; age; duration of array exposure to the skin; and the criticality of proper array application to the skin. Part II will be a randomized study in which doxorubicin-containing arrays will be applied to subjects demonstrated by biopsy to have basal cell cancer. A subject will be randomized to one of four dose groups: placebo microneedle array and 50 µg, 100 µg, and 200 µg doses of doxorubicin in a tip-loaded, dissolvable microneedle arrays (D-MNA).

NCT ID: NCT04552990 Active, not recruiting - Clinical trials for Basal Cell Carcinoma

Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma

Start date: September 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether injecting ALA into the skin with a jet-injection device and activating the drug with light is a safe treatment that causes few or mild side effects in people with basal cell carcinoma.

NCT ID: NCT02367547 Active, not recruiting - Clinical trials for Carcinoma, Basal Cell

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

Start date: March 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This pilot study compares three photosensitisers, hexylaminolevulinate (HAL) and aminolevulinic acid nano emulsion (BF-200 ALA) to methylaminolevulinate (MAL) in photodynamic therapy of superficially growing basal cell carcinomas. Study is conducted using randomised prospective double blinded comparing design. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up before and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years.